Stock 8STN SORRENTO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Sorrento Therapeutics, Inc. Stock Deutsche Boerse AG

Equities

8STN

US83587F2020

Biotechnology & Medical Research

Financials

Sales 2021 52.9M 48.55M 72.35M Sales 2022 62.84M 57.67M 85.93M Capitalization 411M 378M 563M
Net income 2021 -428M -393M -585M Net income 2022 -573M -526M -784M EV / Sales 2021 29.1 x
Net Debt 2021 111M 102M 151M Net Debt 2022 84.53M 77.57M 116M EV / Sales 2022 7.89 x
P/E ratio 2021
-3.2 x
P/E ratio 2022
-0.65 x
Employees 949
Yield 2021 *
-
Yield 2022
-
Free-Float 97.77%
More Fundamentals * Assessed data

Chart Sorrento Therapeutics, Inc.

Dynamic Chart

Latest news about Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Emerged from Bankruptcy CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
Final DIP Financing Approved for Sorrento Therapeutics, Inc. CI
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc. CI
Motion for Asset Sale Approved for Sorrento Therapeutics, Inc. CI
Interim DIP Financing Approved for Sorrento Therapeutics, Inc. CI
Health Care Slips on Growth Doubts -- Health Care Roundup DJ
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc. CI
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc. CI
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc. CI
Second Modified Joint Liquidation Plan and DIscllosure Statement Approved for Sorrento Therapeutics, Inc. CI
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90 CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Chief Financial Officer CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million. CI
More news

Analyst Recommendations on Sorrento Therapeutics, Inc.

Dawson James Downgrades Sorrento Therapeutics to Neutral Rating From Buy MT
Cantor Fitzgerald Initiates Sorrento Therapeutics at Overweight With $5 Price Target MT
HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $20 From $26, Reiterates Buy Rating MT
SORRENTO THERAPEUTICS : HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $26 From $30, Keeps Buy Rating MT
SORRENTO THERAPEUTICS : B. Riley Starts Sorrento Therapeutics at Buy With $26 Price Target MT
More recommendations

Press releases Sorrento Therapeutics, Inc.

Ninth Circuit Rules That Biopharmaceutical Company's Announcement Of COVID-19 "Cure" Did Not Violate Securities Laws AQ
Ninth Circuit Affirms Dismissal Of Putative Securities Class Action Against Biopharmaceutical Company Over Statements It Had Developed A COVID "Cure" AQ
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend AQ
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024 AQ
Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company AQ
More press releases

News in other languages on Sorrento Therapeutics, Inc.

Wall Street lager gesloten
Fors lagere koersen op Wall Street
Fors lagere opening Wall Street op til
Sorrento gaat samenwerking aan met Mayo Clinic
Borsa Usa incerta in vista di primo dibattito presidenziale
More news

Managers and Directors - Sorrento Therapeutics, Inc.

Managers TitleAgeSince
Henry Ji CEO
 Chief Executive Officer 59 88-12-31
Shawn Sahebi COO
 Chief Operating Officer - -
Mike A. Royal CTO
 Chief Tech/Sci/R&D Officer 70 14-03-02
Members of the board TitleAgeSince
Kim D. Janda BRD
 Director/Board Member 67 12-03-31
David Lemus BRD
 Director/Board Member 61 17-09-30
Jaisim Shah BRD
 Director/Board Member 63 13-09-10
More insiders

Company Profile

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.17% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+24.67% 117B
ARGENX SE Stock argenx SE
+25.44% 27.67B
BIONTECH SE Stock BioNTech SE
-17.74% 20.33B
GENMAB A/S Stock Genmab A/S
-15.17% 16.79B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.21% 15.63B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.91% 14.84B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.10% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+54.50% 14.43B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SRNE Stock
  4. 8STN Stock